PRE-IVF TREATMENT WITH A GNRH ANTAGONIST IN WOMEN WITH ENDOMETRIOSIS (PREGNANT): STUDY PROTOCOL FOR A PROSPECTIVE, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.

Taylor H, Li HJ, Carson S, Flores V, Pal L, Robbins J, Santoro NF, Segars JH, Seifer D, Huang H, Young S, Zhang H. Pre-IVF treatment with a GnRH antagonist in women with endometriosis (PREGNANT): study protocol for a prospective, double-blind, placebo-controlled trial. BMJ Open. 2022 Jun 17;12(6):e052043. doi: 10.1136/bmjopen-2021-052043. PMID: 35715184; PMCID: PMC9207753.

Women diagnosed with endometriosis-associated infertility are often successfully treated with IVF. The PREGnant study utilizes an oral GnRH antagonist to treat endometriosis prior to IVF start; the efficacy of the treatment will be assessed using live birth rates. This publication further explains the study protocol.

Previous
Previous

PERCEPTION OF PAIN AND THE OOCYTE DONOR EXPERIENCE: A RETROSPECTIVE ANALYSIS OF COMMERCIAL US DONORS.

Next
Next

NORMALISING MENOPAUSE.